Animal studies revealed that rosiglitazone exerted its anti-depressant effect by upregulating hippocampal CPE expression and neurogenesis, suggesting a possible role of NFα1/CPE in the treatment of depression (Cheng et al., 2015). Here, CPE is linked to depressive disorder.